A multicenter, international study on cardiovascular safety and renal microvascular outcome.  There will be a randomized parallel group, it is double-blind, and placebo-controlled. For patients with type 2 diabetes mellitus at high vascular risk, Using LINAgliptin, 5 mg once a day.